A scientific advisory board is a group of outside experts, usually senior researchers or clinicians, who give a company non-binding guidance on the science behind its products and strategy. The board has no decision-making authority, and its members owe no fiduciary duty to the company. That makes it fundamentally different from a corporate board of directors, and the difference drives everything else: how members are recruited, what they sign, how they are paid, and which federal rules reach them personally.
What a Scientific Advisory Board Actually Does
The defining feature is advice without authority. A board of directors is legally responsible for the organization and owes duties of care, loyalty, and obedience; it votes on budgets, hires, and strategy. An SAB recommends. Management is free to accept the input, weigh it against other factors, or ignore it entirely.1Michigan State University Extension. Understanding Roles: Board of Directors vs. Advisory Boards
That absence of legal responsibility is the point. Because advisors face no liability for the company’s choices, they can speak candidly without worrying about shareholder suits, and companies can recruit scientists who would never accept a director’s time commitment and personal risk. The trade-off is leverage: SAB recommendations carry no binding force.
Blurring the line creates real exposure. If an SAB member starts approving expenditures, directing staff, or making operational calls, a court can treat them as a de facto director with the fiduciary obligations that attach. Keeping the role genuinely advisory is a legal protection, not a formality.
Core Advisory Functions
SAB work centers on pressure-testing the science beneath a company’s strategy. Typical activities include:
- Pipeline review. Assessing whether preclinical data supports advancing a program, whether experimental designs are sound, and whether a candidate product holds up under scrutiny.
- Clinical trial guidance. Advising on trial design, endpoint selection, and protocol structure so studies meet FDA expectations for each phase of development.2Food and Drug Administration. IND Applications for Clinical Investigations: Clinical Protocols
- Technology landscape. Forward-looking reads on emerging technologies, competitive threats, and scientific trends the company should anticipate.
- Intellectual property strategy. Identifying patentable discoveries, evaluating the strength of existing patents, and flagging freedom-to-operate issues early.
The value depends on members engaging with internal data. Boards that meet once a year for a slide deck and dinner rarely justify their cost. Effective ones work through raw datasets, push back on assumptions management would rather leave alone, and sometimes deliver the unwelcome news that a lead program has a fatal flaw.
Who Serves on an SAB
Members are typically researchers, clinicians, or industry veterans with terminal degrees and a record of publication, patents, or product development in the relevant field. Selection aims for coverage across the company’s key technical areas. A gene therapy company might recruit a virologist, a manufacturing expert, a clinical immunologist, and a regulatory scientist.
Independence governs the vetting. Candidates are screened for financial holdings in competitors, consulting relationships that could compromise objectivity, and equity positions that might color their advice. Academic members bring an extra layer: most research universities impose their own conflict-of-interest policies on outside advisory work. Faculty generally must keep SAB service separate from university research, disclose equity compensation, and avoid giving a company early or exclusive access to unpublished findings. Discoveries that surface during advisory work may also trigger disclosure to the university’s technology licensing office.
These restrictions matter because many SAB members hold faculty posts. A company that ignores a university’s policies risks losing its advisor or raising questions about research integrity. Ask prospective members about their institutional requirements before finalizing an appointment.
The Advisory Agreement
Every SAB relationship should be documented in a written contract. These agreements are not boilerplate. They define the scope of services, set pay, and lock in confidentiality and intellectual property obligations that outlast the engagement itself.
Confidentiality
SAB members see proprietary data, unpublished results, and strategic plans. The agreement will require them to hold all of it in strict confidence, usually for a period extending well past the end of the relationship. In the Erasca SAB agreement filed with the SEC, the advisor agreed to “hold in strictest confidence and will not disclose, use, lecture upon or publish any of the Company’s Proprietary Information” unless performing requested services or authorized in writing.3U.S. Securities and Exchange Commission. Erasca, Inc. Scientific Advisory Board Agreement
Intellectual Property Assignment
This is where advisors are most often caught off guard. Standard SAB agreements require the advisor to assign to the company all rights in inventions, discoveries, or works created during or in connection with the engagement. One SEC-filed agreement requires the advisor to “assign to the Company, or its designee, any and all rights, title, and interests” in inventions conceived “within the scope of that engagement,” and treats original works created during the engagement as “works made for hire.”4U.S. Securities and Exchange Commission. Advisory Board Agreement
For academic researchers, that clause can conflict with university policies that require faculty to assign inventions to the institution. Anyone with an active research program should read the IP clause closely and negotiate carve-outs for work outside the advisory scope before signing.
Exclusivity
Some agreements restrict consulting for competitors or require written approval before new engagements. The AVEO Pharmaceuticals SAB agreement prohibited the advisor from consulting with any other for-profit entity without the company’s prior written approval, though the company had to respond within ten days or approval was deemed automatic.5U.S. Securities and Exchange Commission. Consulting and Scientific Advisory Board Agreement – AVEO Pharmaceuticals, Inc. Terms vary widely from no exclusivity at all to tight restrictions. Negotiate before signing.
Compensation and Tax Treatment
SAB pay typically comes in three forms: a cash retainer paid quarterly or annually, per-meeting or hourly fees, and equity grants meant to align the advisor’s interest with the company’s success.
Amounts vary. One publicly filed agreement set a $50,000 annual retainer plus $750 per hour for meeting attendance, capped at $75,000 per year.5U.S. Securities and Exchange Commission. Consulting and Scientific Advisory Board Agreement – AVEO Pharmaceuticals, Inc. Another offered $650 per hour for services beyond standard SAB duties, with the main compensation coming through stock options.3U.S. Securities and Exchange Commission. Erasca, Inc. Scientific Advisory Board Agreement Early-stage companies lean on equity because they lack cash for large retainers.
Advisor equity is usually granted as non-qualified stock options rather than incentive stock options. Vesting is often shorter than employee grants, commonly running two years with monthly vesting and no cliff, which reflects the expectation that advisors deliver most of their value early.
Contractor Classification
SAB members are almost always independent contractors, not employees. The IRS treats a worker as a contractor when the client controls the result of the work but not the methods used to achieve it.6Internal Revenue Service. Independent Contractor Defined SAB members set their own schedule, work from their own facilities, and exercise independent judgment.
That classification carries tax consequences. SAB compensation is subject to self-employment tax at a combined 15.3%, covering both the employer and employee shares of Social Security (12.4%) and Medicare (2.9%).7Internal Revenue Service. Self-Employment Tax (Social Security and Medicare Taxes) The company does not withhold income tax or FICA. For tax years beginning in 2026, the reporting threshold for certain information returns, including payments to independent contractors, increased to $2,000 from the previous $600 floor.8Internal Revenue Service. 2026 Publication 1099 Advisors paid above that amount should expect a Form 1099-NEC.
Governance and Meetings
An SAB usually reports to a senior executive, often the Chief Scientific Officer or CEO, who serves as the primary liaison with company leadership. That direct line keeps recommendations from dying in middle management.
Meeting frequency varies. Most SABs convene quarterly or semi-annually for formal sessions, with ad-hoc consultations for urgent matters like unexpected clinical results or a competitive development. Effective meetings require preparation: data packages sent well in advance, and agendas focused on decisions the company actually faces rather than broad scientific education.
Conflict-of-interest disclosure is ongoing, not a one-time check at onboarding. Members should update the company whenever they take on new consulting work, acquire equity in competitors, or begin anything that could compromise their objectivity. The advisory agreement typically formalizes the duty, but the underlying principle is simple: the company needs to know when an advisor’s other commitments might color their judgment.
Insider Trading Exposure
SAB members in the life sciences routinely receive material nonpublic information: clinical trial results, regulatory submissions, strategic plans that can move a stock price. Trading on that information, or tipping someone else to trade, violates Section 10(b) of the Securities Exchange Act and SEC Rule 10b-5.9Office of the Law Revision Counsel. 15 U.S. Code 78j – Manipulative and Deceptive Devices
Enforcement reaches well beyond company executives. In January 2026, the SEC filed suit against a biostatistical consultant who allegedly traded on positive clinical trial results he learned about while consulting for a pharmaceutical company, generating nearly $490,000 in profits.10U.S. Securities and Exchange Commission. Hong (John) Wang and Precision Clinical Consulting, LLC Even modest profits or avoided losses based on confidential information can trigger an investigation. Advisors who hold equity should be careful about the timing of option exercises, because trades placed shortly before a major announcement are exactly what SEC surveillance tools look for.
Sunshine Act Reporting for Physician Members
When a pharmaceutical or medical device company pays a physician to serve on its SAB, federal transparency rules apply. Under 42 U.S.C. ยง 1320a-7h, any applicable manufacturer must report to the Centers for Medicare and Medicaid Services all payments or transfers of value made to covered recipients, including consulting fees, honoraria, stock or stock options, travel, and food.11Office of the Law Revision Counsel. 42 U.S. Code 1320a-7h – Transparency Reports and Reporting of Physician Ownership or Investment Interests
The thresholds are low. For program year 2026, individual payments of $13.82 or more must be reported, and if aggregate payments to a single recipient exceed $138.13 in a calendar year, all payments to that recipient must be disclosed regardless of individual amounts.12Centers for Medicare & Medicaid Services. Data Collection for Open Payments Reporting Entities The reported data becomes publicly searchable in the CMS Open Payments database. Applicable manufacturers include any company producing at least one product reimbursed by Medicare, Medicaid, or CHIP that operates in the United States.13Centers for Medicare & Medicaid Services. Reporting Entities
The filing obligation sits with the company, but physician members should understand that their compensation becomes public. That visibility can affect how their objectivity is viewed when they publish research, speak at conferences, or make clinical recommendations touching the company’s products.
Private SABs vs. Federal Advisory Committees
One boundary worth drawing. A private company’s SAB operates under contract law and whatever governance the company sets. A federal advisory committee operates under the Federal Advisory Committee Act, now codified at 5 U.S.C. Chapter 10, which has no parallel in the private sector.14Office of the Law Revision Counsel. 5 USC Ch. 10: Federal Advisory Committees Government advisory committees must file a formal charter, hold public meetings with advance notice in the Federal Register, and maintain membership that is “fairly balanced in terms of the points of view represented.” A private SAB can meet behind closed doors, choose its membership freely, and continue indefinitely.
The distinction matters because FDA and other agencies run their own advisory committees, and the phrase “scientific advisory board” gets used loosely in both settings. A physician invited to serve on an FDA advisory committee faces disclosure requirements, recusal rules, and public scrutiny well beyond anything a private-sector SAB imposes. Before accepting an invitation, clarify whether the body is a private consultative panel or a government committee subject to FACA.